Research programme: excitatory amino acid antagonists - Neurocrine Biosciences/Wyeth
Alternative Names: NBI-59159Latest Information Update: 24 Feb 2011
At a glance
- Originator Neurocrine Biosciences
- Developer Neurocrine Biosciences; Wyeth
- Class
- Mechanism of Action Excitatory amino acid antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Retinal disorders; Schizophrenia; Stroke
Most Recent Events
- 12 Aug 2009 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
- 12 Aug 2009 No development reported - Preclinical for Retinal disorders in USA (unspecified route)
- 12 Aug 2009 No development reported - Preclinical for Schizophrenia in USA (unspecified route)